PMID- 31202428
OWN - NLM
STAT- MEDLINE
DCOM- 20200213
LR  - 20220716
IS  - 1532-8686 (Electronic)
IS  - 0037-1963 (Print)
IS  - 0037-1963 (Linking)
VI  - 56
IP  - 3
DP  - 2019 Jul
TI  - Post-transplantation cyclophosphamide to facilitate HLA-haploidentical 
      hematopoietic cell transplantation: Mechanisms and results.
PG  - 183-189
LID - S0037-1963(18)30133-1 [pii]
LID - 10.1053/j.seminhematol.2018.09.002 [doi]
AB  - Allogeneic blood or marrow transplantation (BMT) is a curative therapy for a 
      number of high-risk hematologic malignancies. Historically, only patients with a 
      human leukocyte antigen (HLA)-matched sibling or unrelated donor were able to 
      receive this therapy, thus excluding many potential transplant recipients. In 
      recent years, partially mismatched related donor, or human leukocyte 
      antigen-haploidentical (haplo) BMT has expanded the donor pool to nearly every 
      patient in need of a transplant, particularly when using post-transplantation 
      cyclophosphamide to promote immune tolerance and prevent graft-versus-host 
      disease. With now over 15 years of clinical experience using this platform, long 
      terms outcomes are well understood. We review the clinical literature and 
      highlight the advantages and disadvantages of haplo BMT with post-transplantation 
      cyclophosphamide.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Elmariah, Hany
AU  - Elmariah H
AD  - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins 
      University School of Medicine, Baltimore, MD.
FAU - Fuchs, Ephraim J
AU  - Fuchs EJ
AD  - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins 
      University School of Medicine, Baltimore, MD. Electronic address: 
      fuchsep@jhmi.edu.
LA  - eng
GR  - P01 CA015396/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20180920
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents, Alkylating/pharmacology/*therapeutic use
MH  - Cyclophosphamide/pharmacology/*therapeutic use
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Male
MH  - Transplantation Conditioning/*methods
PMC - PMC9229262
MID - NIHMS1507607
OTO - NOTNLM
OT  - Cyclophosphamide
OT  - Graft-versus-host disease
OT  - Hematopoietic cell transplantation
OT  - Histocompatibility
OT  - Human leukocyte antigens
COIS- Conflicts of Interest/Disclosures The authors declare that they have no conflicts 
      of interest or competing financial or personal relationships that could 
      inappropriately influence the content of this article.
EDAT- 2019/06/17 06:00
MHDA- 2020/02/14 06:00
PMCR- 2022/06/24
CRDT- 2019/06/17 06:00
PHST- 2018/08/26 00:00 [received]
PHST- 2018/09/15 00:00 [accepted]
PHST- 2019/06/17 06:00 [entrez]
PHST- 2019/06/17 06:00 [pubmed]
PHST- 2020/02/14 06:00 [medline]
PHST- 2022/06/24 00:00 [pmc-release]
AID - S0037-1963(18)30133-1 [pii]
AID - 10.1053/j.seminhematol.2018.09.002 [doi]
PST - ppublish
SO  - Semin Hematol. 2019 Jul;56(3):183-189. doi: 10.1053/j.seminhematol.2018.09.002. 
      Epub 2018 Sep 20.